Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.3630 +0.0003 (+0.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,441,396
Open 0.3705
Bid (Size) 0.3602 (200)
Ask (Size) 0.3680 (2,600)
Prev. Close 0.3627
Today's Range 0.3550 - 0.3753
52wk Range 0.3508 - 3.620
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
From Context Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-76.6%
-76.6%
1 Month
-41.6%
-41.6%
3 Month
-82.1%
-82.1%
6 Month
-87.3%
-87.3%
1 Year
-56.9%
-56.9%

More News

Read More
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Context Therapeutics Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Context Therapeutics Inc. - Common Stock publicly traded?
Yes, Context Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Context Therapeutics Inc. - Common Stock trade on?
Context Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Context Therapeutics Inc. - Common Stock?
The ticker symbol for Context Therapeutics Inc. - Common Stock is CNTX on the Nasdaq Stock Market
What is the current price of Context Therapeutics Inc. - Common Stock?
The current price of Context Therapeutics Inc. - Common Stock is 0.3630
When was Context Therapeutics Inc. - Common Stock last traded?
The last trade of Context Therapeutics Inc. - Common Stock was at 09/03/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS